BLPH VS JNJ Stock Comparison

Performance

BLPH
10/100

BLPH returned -90.60% in the last 12 months. Based on SPY's performance of -11.83%, its performance is below average giving it a score of 10 of 100.

JNJ
73/100

JNJ returned -15.84% in the last 12 months. Based on SPY's performance of -20.60%, its performance is above average giving it a score of 73 of 100.

Analyst Price Targets

BLPH
75/100

1 analysts offer 12-month price targets for BLPH. Together, they have an average target of 19, the most optimistic target put BLPH at 19 within 12-months and the most pessimistic has BLPH at 19. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

JNJ
63/100

23 analysts offer 12-month price targets for JNJ. Together, they have an average target of 176.5, the most optimistic target put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Technicals

BLPH
11/100

BLPH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

JNJ
14/100

JNJ receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.

Earnings

BLPH
36/100

BLPH has missed earnings 3 times in the last 20 quarters.

JNJ
100/100

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

BLPH
10/100

Out of the last 20 quarters, BLPH has had 2 profitable quarters and has increased their profits year over year on 1 of them.

JNJ
74/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

BLPH
57/100

BLPH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.

JNJ
43/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Sentiment

BLPH

"Sentiment" not found for BLPH

JNJ
72/100

JNJ had a bullish sentiment score of 71.87% across Twitter and StockTwits over the last 12 months. It had an average of 205.31 posts, 3,341.61 comments, and 16,552.61 likes per day.

Dividend

BLPH

"Dividend" not found for BLPH

JNJ
100/100

JNJ's most recent dividend was $0.90 per share, based on a share price of $145.60. It was a payout ratio of 61.39% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Bellerophon Therapeutics, Inc. Summary

Nasdaq / BLPH

Healthcare

Biotechnology

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Johnson & Johnson Summary

New York Stock Exchange / JNJ

Healthcare

Drug Manufacturers - General

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Power up your portfolio